Dacomitinib (PF-00299804)

DRUG3 trials

Conditions

Carcinoma, Non-small CellNon-Small Cell Lung CancerNon-small Cell Lung Cancer With EGFR-Activating Mutations

Phase 2

Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung

CompletedNCT00818441

PfizerCarcinoma, Non-small Cell

Start: 2009-03-11End: 2015-04-30Updated: 2019-01-08

Phase 3

ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer

CompletedNCT01360554

PfizerNon-Small Cell Lung Cancer

Start: 2011-06-16End: 2015-09-14Updated: 2017-05-24

ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.

CompletedNCT01774721

PfizerNon-small Cell Lung Cancer With EGFR-Activating Mutations

Start: 2013-05-09End: 2022-01-27Updated: 2023-11-14

Journal of Cachexia Sarcopenia and Muscle2026-05-13

Real-world use of and clinical outcomes with dacomitinib as first-line therapy in Asian patients with EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer: Final analysis of the ARIA study.

2025-11-25

Efficacy in patients with EGFR -positive non-small-cell lung cancer treated with dacomitinib who had skin adverse events: post hoc analyses from ARCHER 1050

Future Oncology2024-10-033 citations

Protein Kinase Inhibitors Indicated for Lung Cancer: Pharmacodynamics, Pharmacokinetics, Adverse Drug Reactions, and Evaluation in Clinical Trials

Journal of Clinical Pharmacy and Therapeutics2024-01-013 citations

Evaluation of the Effect of Proton Pump Inhibitors on the Efficacy of Dacomitinib and Gefitinib in Patients with Advanced Non-Small Cell Lung Cancer and EGFR-Activating Mutations.

2021-06-137 citations

Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050).

2021-02-2336 citations

Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.

2021-02-0183 citations

Effects of Dose Modifications on the Safety and Efficacy of Dacomitinib for EGFR Mutation-Positive Non-Small-Cell Lung Cancer

Future Oncology2019-07-1735 citations

Dacomitinib, a second-generation irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) to treat non-small cell lung cancer.

2019-04-0114 citations

The effect of proton pump inhibitors (PPI) on dacomitinib (DACO) pharmacokinetics and efficacy in non-small cell lung cancer (NSCLC) patients with activating epidermal growth factor receptor (EGFR) mutation

Annals of Oncology2019-04-01

Dacomitinib (daco) versus gefitinib (gef) for first-line treatment of advanced NSCLC (ARCHER 1050): Final overall survival (OS) analysis.

Journal of Clinical Oncology2018-05-2011 citations

Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.

2017-09-25882 citations

Dacomitinib versus gefitinib for the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer (ARCHER 1050): A randomized, open-label phase III trial.

Journal of Clinical Oncology2017-06-1333 citations

Second-line Treatment of Non-Small Cell Lung Cancer: Focus on the Clinical Development of Dacomitinib.

2017-04-059 citations

Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials.

2016-01-1340 citations

Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials

QUT ePrints (Queensland University of Technology)2016-01-01

Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors.

2015-04-21250 citations

Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial.

2014-11-0589 citations

Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial.

2014-10-1597 citations

Randomized, double-blinded study of dacomitinib, an irreversible pan-human epidermal growth factor receptor (HER) inhibitor, versus erlotinib for second-line/third-line therapy of locally advanced/metastatic non-small cell lung cancer (ARCHER 1009).

Journal of Clinical Oncology2014-05-2016 citations

2 more papers not shown

Dacomitinib (PF-00299804)

Sponsors

Conditions

Phase 2

Phase 3

Related Papers